产品
编 号：F743347
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1229575-09-0
产品详情
生物活性：
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.
体内研究：
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice.Animal Model:NSG mice with CART19 cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; daily; 10 days
Result:Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI).
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.
体内研究：
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice.Animal Model:NSG mice with CART19 cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; daily; 10 days
Result:Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备